1018 related articles for article (PubMed ID: 29228202)
1. Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015-16.
Livermore DM; Meunier D; Hopkins KL; Doumith M; Hill R; Pike R; Staves P; Woodford N
J Antimicrob Chemother; 2018 Mar; 73(3):648-657. PubMed ID: 29228202
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the
Viala B; Zaidi FZ; Bastide M; Dumont Y; Le Moing V; Jean-Pierre H; Godreuil S
Microb Drug Resist; 2019 Nov; 25(9):1325-1329. PubMed ID: 31225764
[No Abstract] [Full Text] [Related]
3.
Karlowsky JA; Kazmierczak KM; Bouchillon SK; de Jonge BLM; Stone GG; Sahm DF
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760124
[TBL] [Abstract][Full Text] [Related]
4.
Karlowsky JA; Kazmierczak KM; Bouchillon SK; de Jonge BLM; Stone GG; Sahm DF
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670424
[TBL] [Abstract][Full Text] [Related]
5. Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
Alatoom A; Elsayed H; Lawlor K; AbdelWareth L; El-Lababidi R; Cardona L; Mooty M; Bonilla MF; Nusair A; Mirza I
Int J Infect Dis; 2017 Sep; 62():39-43. PubMed ID: 28610832
[TBL] [Abstract][Full Text] [Related]
6. Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from U.S. Medical Centers, 2013 to 2016.
Sader HS; Castanheira M; Shortridge D; Mendes RE; Flamm RK
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28827415
[TBL] [Abstract][Full Text] [Related]
7. Ceftazidime-Avibactam Antimicrobial Activity and Spectrum When Tested Against Gram-negative Organisms From Pediatric Patients: Results From the INFORM Surveillance Program (United States, 2011-2015).
Sader HS; Huband MD; Duncan LR; Flamm RK
Pediatr Infect Dis J; 2018 Jun; 37(6):549-554. PubMed ID: 29206750
[TBL] [Abstract][Full Text] [Related]
8. Selection of mutants with resistance or diminished susceptibility to ceftazidime/avibactam from ESBL- and AmpC-producing Enterobacteriaceae.
Livermore DM; Mushtaq S; Doumith M; Jamrozy D; Nichols WW; Woodford N
J Antimicrob Chemother; 2018 Dec; 73(12):3336-3345. PubMed ID: 30247546
[TBL] [Abstract][Full Text] [Related]
9. Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients.
Zamudio R; Hijazi K; Joshi C; Aitken E; Oggioni MR; Gould IM
Int J Antimicrob Agents; 2019 Jun; 53(6):774-780. PubMed ID: 30831233
[TBL] [Abstract][Full Text] [Related]
10. Global Dissemination of blaKPC into Bacterial Species beyond Klebsiella pneumoniae and In Vitro Susceptibility to Ceftazidime-Avibactam and Aztreonam-Avibactam.
Kazmierczak KM; Biedenbach DJ; Hackel M; Rabine S; de Jonge BL; Bouchillon SK; Sahm DF; Bradford PA
Antimicrob Agents Chemother; 2016 Aug; 60(8):4490-500. PubMed ID: 27161636
[TBL] [Abstract][Full Text] [Related]
11. The postantibiotic effect and post-β-lactamase-inhibitor effect of ceftazidime, ceftaroline and aztreonam in combination with avibactam against target Gram-negative bacteria.
Pillar CM; Stoneburner A; Shinabarger DL; Krause KM; Nichols WW
Lett Appl Microbiol; 2016 Aug; 63(2):96-102. PubMed ID: 27221329
[TBL] [Abstract][Full Text] [Related]
12. Activity of ceftolozane/tazobactam against surveillance and 'problem' Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles.
Livermore DM; Mushtaq S; Meunier D; Hopkins KL; Hill R; Adkin R; Chaudhry A; Pike R; Staves P; Woodford N;
J Antimicrob Chemother; 2017 Aug; 72(8):2278-2289. PubMed ID: 28520867
[TBL] [Abstract][Full Text] [Related]
13. WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D β-lactamases.
Mushtaq S; Vickers A; Woodford N; Livermore DM
J Antimicrob Chemother; 2017 Jun; 72(6):1688-1695. PubMed ID: 28333319
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of ceftazidime/avibactam against isolates of Enterobacteriaceae collected in European countries: INFORM global surveillance 2012-15.
Kazmierczak KM; de Jonge BLM; Stone GG; Sahm DF
J Antimicrob Chemother; 2018 Oct; 73(10):2782-2788. PubMed ID: 30010894
[TBL] [Abstract][Full Text] [Related]
15. Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the
Yin D; Wu S; Yang Y; Shi Q; Dong D; Zhu D; Hu F;
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30617091
[TBL] [Abstract][Full Text] [Related]
16. Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae.
Haidar G; Clancy CJ; Chen L; Samanta P; Shields RK; Kreiswirth BN; Nguyen MH
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630202
[TBL] [Abstract][Full Text] [Related]
17. Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and β-lactamases with ceftazidime hydrolytic activity lead to elevated MIC values.
Castanheira M; Doyle TB; Hubler C; Sader HS; Mendes RE
Int J Antimicrob Agents; 2020 Jul; 56(1):106011. PubMed ID: 32417206
[TBL] [Abstract][Full Text] [Related]
18. The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa.
Gill CM; Aktaþ E; Alfouzan W; Bourassa L; Brink A; Burnham CD; Canton R; Carmeli Y; Falcone M; Kiffer C; Marchese A; Martinez O; Pournaras S; Satlin M; Seifert H; Thabit AK; Thomson KS; Villegas MV; Nicolau DP;
Eur J Clin Microbiol Infect Dis; 2021 Dec; 40(12):2533-2541. PubMed ID: 34291323
[TBL] [Abstract][Full Text] [Related]
19. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
Castanheira M; Duncan LR; Mendes RE; Sader HS; Shortridge D
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263073
[TBL] [Abstract][Full Text] [Related]
20. ESBLs and resistance to ceftazidime/avibactam and ceftolozane/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa.
Ortiz de la Rosa JM; Nordmann P; Poirel L
J Antimicrob Chemother; 2019 Jul; 74(7):1934-1939. PubMed ID: 31225611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
